These findings, supported by fluorescence in situ hybridization (FISH) analysis of c-MET amplification in human cancer tissues, suggest telisotuzumab’s potential clinical benefit for treating cancers with c-MET amplification (85, 86). The gene discussed is MET; the disease is cancer.